Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

biotech_invest 122 posts  |  Last Activity: 9 hours ago Member since: Mar 5, 1998
  • Reply to

    If Anyone Wants to Sell Today ...

    by tb00tb00a Jan 19, 2016 2:49 PM
    biotech_invest biotech_invest Jan 19, 2016 3:59 PM Flag

    LOL! What about the possibility to have 50% losses when you are buying PRAN at $0.50? You never believe me when I was saying that PRAN pps will decline from $1 to $0.50. And now you don't believe that it can easy decline from $0.50 to $0.25? Or even to $0.15?
    So, if you are really buying PRAN for $0.50 be ready for huge and irreversible losses.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Jan 19, 2016 10:26 AM Flag

    so, kad, you predict that nothing will happen with IND for Prana Ph3 HD after 1 year on PCH? And FDA will just wait and wait and wait infinitely for Complete Response from Prana and do nothing?
    It's clearly for everybody that Prana management failed to collect all safety data for PBT2 high doses, analyse them and combine into Complete Response that will persuade FDA to lift PCH for PBT2 250 mg daily dosing. After Feb 13, 2016 FDA will switch Ph3 HD IND to inactive status and Prana will notify shareholders that company will continue to work with FDA during next year. Do you think such "good news" will induce pps spike to $1? Most likely it will decline to $0.10-0.15 range. Prana cash will melt and finally evaporate during next 2-3 years and the company will file a bankruptcy in 2017.

    Sentiment: Strong Sell

  • at least to attempt to lift this hold. What is the reason of the absence of such attempt? They said that they hired some team of experts to resolve PCH problems. Again lied? I'm not surprised.
    Next month FDA will said that IND of Ph3 HD is in inactive status i.e. the trial will not start with demanded PBT2 dose 250 mg daily. May be Prana will agree to dose 100 mg PBT2? It will be interesting to see market reaction on such "good news" :-) Can we see pps $0.25 after PCH lift with 100 mg PBT2 daily? Most likely.

    Sentiment: Strong Sell

  • cognition decline. Big Pharma see no potential in PBT2 as AD or HD drug. If they see they will pay upfront money and negotiate royalties. Look at ORMP: they fooled even Chinese pharma with oral insulin pills and got upfront money and royalties.
    Questions for PRAN pumpers: why Prana doesn't have any partnership for PBT2 AD or HD?

    Sentiment: Strong Sell

  • such possibility? Impossibly? May be they hope that Tanzi will publish a paper about PBT2 saved neurons growing in Petri from AD and this publication will induce a massive pps jump? It's very unlikely.
    Prana management silence during next month will kill this stock. They must say what is going on with PCH before Feb 2016 when FDA will put IND of Ph3 HD to inactive status.
    Inactive IND status for Ph3 HD = $0.20 pps for PRAN.

    Sentiment: Strong Sell

  • saying that Mannkind is dead. "Even if millions are saying YES, I'm answering NO"
    Mann is rich and can always save his company by infusion of 50 millions but who will save Prana? Pumpers still pushing an idea that Prana will lift PCH before FDA put IND of Ph3 HD to inactive status but it's very unlikely. There is only one way to lift PCH for Prana: agree to dose patients with 100 mg PBT2 daily. Trial will take 2-3 years and Prana management will have enough time to prepare another fake project like PD drug.
    Question is will PRAN pps jump if Prana notify investors that PCH is lifted but dosing is 100 mg PBT2 daily now? May be yes. Some investors will just see that PRAN is biotech that has HD drug in Phase 3 and buy a stock.
    So, let's wait a couple weeks more and see what kind of news they are preparing for holders.

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Jan 4, 2016 7:32 PM Flag

    come on, inter :-) just do some search about FDA rules about PCH

    "If a sponsor of an IND that has been placed on clinical hold requests in writing that the clinical hold be removed and submits a complete response to the issue(s) identified in the clinical hold order, FDA shall respond in writing to the sponsor within 30-calendar days of receipt of the request and the complete response. FDA's response will either remove or maintain the clinical hold, and will state the reasons for such determination. Notwithstanding the 30-calendar day response time, a sponsor may not proceed with a clinical trial on which a clinical hold has been imposed until the sponsor has been notified by FDA that the hold has been lifted.
    (f) Appeal. If the sponsor disagrees with the reasons cited for the clinical hold, the sponsor may request reconsideration of the decision in accordance with 312.48.
    (g) Conversion of IND on clinical hold to inactive status. If all investigations covered by an IND remain on clinical hold for 1 year or more, the IND may be placed on inactive status by FDA under 312.45."
    For PRAN Ph3 HD 1 year will be Feb, 2016 i.e. next month.

    Sentiment: Strong Sell

  • If FDA doesn't get CLINICAL HOLD COMPLETE RESPONSE from Prana before Feb, 2016 they will cancel IND with 250 mg PBT2 daily. However, other treatments like 100 mg PBT2 daily (if part of the protocol) are allowed to proceed under the IND. Question is will Prana start Ph3 HD with 100 mg PBT2 daily?
    There are 2 scenarios: 1) they will agree to start Ph3 HD with 100 mg PBT2 daily - not good, pps will decline to $0.65 or around; 2) worst case scenario - IND expired and Prana will not start Ph3 HD - stock will be crashed to $0.30 and below.
    Any other variants? PRAN pumpers are welcome to add more optimistic scenarios here. But don't bet on Ph1 PD - it will not save Prana pps from decline and delisting from NASDAQ.

    Sentiment: Strong Sell

  • Game is almost over for Prana: they didn't send in 2015 any Complete Response to FDA with purpose to lift PCH; pps is practically equal to cash level; etc. January 2016 will be terrible month for PRAN: 1 month before IND expiration of Ph3 HD. Of course, desperate Prana management can send a Complete Response in Jan 2016 and notify holders that FDA will respond within 30 calendar days i.e. before Feb 15, 2016. It might be very interesting intrigue: pps can run up to $1-2 during this waiting period. So, some holders that bought PRAN at $0.73 range can make good money.
    Any way, I have no any doubts that Prana will survive in 2016 and continue fooling holders and investors by false promises and hopes. If they fail with Ph3 HD they will try another tramp card i.e. PD. They can easy avoid a delisting by reverse split 1 to 5 or 1 to 10. They have cash positions around $35M and it will provide happy life for Prana management at least for next 2-3 years. They they will file a bankruptcy and disappear. Usual story for scam biotechs like Prana.
    P.S. Good news for Prana pumpers: I'm going to Christmas vacation and will not write any posts before Jan 4, 2016. So, be free and post any false, nonsense and misleading information about "phenomenal achievements" of Prana scientists in AD, HD, PD and other incurable diseases :-)
    Merry Christmas and Happy New Year to all!

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Dec 23, 2015 10:57 AM Flag

    So, Bloomberg also published false statement? "Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study"
    Sue them and win money :-)

    Sentiment: Strong Sell

  • Reply to

    Rolipram

    by juniorsbro Dec 22, 2015 8:02 PM
    biotech_invest biotech_invest Dec 23, 2015 10:55 AM Flag

    don't eat it
    Wiki said:
    "Rolipram was a selective phosphodiesterase-4 inhibitor discovered and developed by Schering AG as a potential antidepressant drug in the early 1990s.[2] It served as a prototype molecule for several companies' drug discovery and development efforts.[3]:668ff Rolipram was discontinued after clinical trials showed that its therapeutic window was too narrow; it could not be dosed at high enough levels to be effective without causing significant gastrointestinal side effects.[3]:

    It continues to be used in research as a well-characterized PDE4 inhibitor.[3]:669 It has been used in studies to understand whether PDE4 inhibition could be useful in autoimmune diseases,[4] Alzheimer's disease,[5] cognitive enhancement,[6] spinal cord injury,[7] and respiratory diseases like asthma and COPD.[8]

  • But when tested in AD patients - see Wikipedia citation below:

    Clinical trials
    PBT2 was the subject of phase II clinical trials for Alzheimer's disease and Huntington's disease. The results for Alzheimer's disease failed to meet its goals,[3][4] and there is no evidence that PBT2 is of any benefit in Alzheimer's dementia.[5] The drug also missed efficacy goals for Huntington's disease.[6][7]

    3) "Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study". Bloomberg News. Mar 31, 2014.
    4) "PBT2 Takes a Dive in Phase 2 Alzheimer's Trial". April 2014.
    5) "There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementia". Cochrane Database of Systematic Reviews: Plain Language Summaries. PubMed Health.
    6) "Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles". thestreet.com.
    7) Huntington Study Group Reach2HD Investigators (2015). "Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial". The Lancet Neurology 14 (1): 39–47. doi:10.1016/S1474-4422(14)70262-5. PMID 25467848.

    If Wiki published a lie about PBT2 you can complain and ask re-write it to: "PBT2 is very effective AD drug and only unusually high response in placebo group prevented to prove it's efficacy in Ph2 AD trial"
    So, call Prana and may be they will correct Wiki :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Dec 22, 2015 4:02 PM Flag

    only one comment: money will not help to discover a cure for AD. They (NIH, NSF, etc) should stop give money to so-called "leading figures in AD research". This money should go to young investigators that are not "slaves" of old and stupid paradigms of AD etiology. If someone had promised to find AD cure 20 years ago and has no drug now funds should stop give him/her grants. The requests for AD grants should be anonymous to avoid the distribution money between these so-called "AD leading scientists".
    There was some funny experiments with science grant requests: 10 requests were send to grant reviewers and they knew the names of each applicant. And these reviewers gave money mostly to "leading scientists". Same 10 requests were anonymous and other reviewers gave money to other applicants (i.e. not the "leading figures") that provided brighter and innovative ideas.
    So, if these $2B go to "AD leading scientists" like Tanzi, Masters, Bush, etc it will waste of money. They will spend all this money on stupid experiments and pushing their "metal theories of AD".
    I hope we will see the first strong kick to amyloid hypothesis of AD in 2016 (TauRx Ph3 AD results for anti-tau drug). Of course, Tanzi will say that PBT2 was specially designed to destroy tau tangles but who will believe him? Prana is already out of AD game and any attempts to return will only accelerate pps decline.

    Sentiment: Strong Sell

  • Reply to

    Wiki about PBT2:

    by biotech_invest Dec 21, 2015 8:38 PM
    biotech_invest biotech_invest Dec 22, 2015 11:48 AM Flag

    Wow! All bunch of PRAN pumpers bite my bait with Wiki PBT2:-) I see tb00, kad, inter... But where is the Rough Kansas Farter (rkf)? Already drunk?
    So, guys, you don't like Wiki because it said that for Prana fake drug "there is no evidence that PBT2 is of any benefit in Alzheimer's dementia.[5] The drug also missed efficacy goals for Huntington's disease"
    And you think that I wrote this paper to Wiki? It's a compliment for me :-)
    So, why Prana not sue Wiki and not force it to withdraw this "lie publication" about PBT2?
    The answer is simple: because it's true. PBT2 is not drug for AD, HD, PD or any other diseases. It's a fake drug. The suggestion to eat it starting from 60 to prevent AD is most stupid idea I ever hear. The statement "PBT2 is a "statin" for AD" should be nominated for most stupid idea in AD research.

    Sentiment: Strong Sell

  • biotech_invest by biotech_invest Dec 21, 2015 8:38 PM Flag

    enDOTwikipediaDOTorg/wiki/PBT2

    PBT2
    From Wikipedia, the free encyclopedia
    PBT2

    PBT2 is an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog[1] intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease.[2]
    Clinical trials
    PBT2 was the subject of phase II clinical trials for Alzheimer's disease and Huntington's disease. The results for Alzheimer's disease failed to meet its goals,[3][4] and there is no evidence that PBT2 is of any benefit in Alzheimer's dementia.[5] The drug also missed efficacy goals for Huntington's disease.[6][7]

    I have nothing to add here :-) Just a fake drug "invented" by scam biotech Prana to fool investors.

    Sentiment: Strong Sell

  • MELBOURNE, AUSTRALIA--(Marketwire -12/15/11)- Prana Biotechnology (NASDAQ: PRAN - News) (ASX: PBT.AX - News) today announced that it has commenced recruitment and screening of patients for a 12 month Phase II Imaging trial testing PBT2, the Company's drug in development for Alzheimer's Disease.
    Screening of patients began last week with psychological tests to measure cognition(1). This week, the first patient was tested for evidence of significant levels of Abeta deposits in the brain(2).
    Professor Colin Masters, Prana consultant and Director of the Mental Health Research Institute, explained that "Prana is selecting patients with established Alzheimer's disease, as well as targeting those very early in the disease process. We are using the most modern techniques available for measuring PBT2's disease modifying effects to establish cognitive, functional and physical changes in the brain. By disease modifying, I mean modifying the rate of progress of Alzheimer's, slowing it down and delaying onset. We are using PiB-PET imaging to measure the drug's effects on the insoluble form of Abeta, and we are using a recently developed blood test to measure levels of the soluble oligomers of Abeta(3). This week we have been taking pre-drug dosing measures of eligible patients to compare with measures that will be taken throughout the trial. Per protocol, each patient qualifying for entry to the trial will receive the first dose of drug or placebo on their second visit to the clinic."
    No one word about tau, only about decreasing of amyloid burden. Kad is lying when said that PBT2 was always anti-tau drug. Only recently Tanzi started to claim PBT2 as anti-tau drug. Any way, it will not help them to fool investors. Just search Wiki for PBT2. Very clear and straight conclusions :-)

    Sentiment: Strong Sell

  • Myeku N et al. 'Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling,' Nature Medicine, Dec. 21, 2015. DOI: 10.1038/nm.4011

    "Using a mouse model of neurodegeneration, the researchers first discovered that tau—a toxic protein that accumulates in Alzheimer's and other brain degenerative diseases—sticks to the proteasome and slows down the protein disposal process.
    Administering rolipram activated the proteasome and restored protein disposal to normal levels. The drug also improved the memory of diseased mice to levels seen in healthy mice.
    Rolipram has been tested before in mice and was shown to improve memory, but the mechanism for how this occurred was unclear. The new research shows that by inhibiting of the PDE-4 enzyme, rolipram produces a physical change in the proteasome that increases its activity.
    "We still don't know exactly where the activation is happening, but what's new is that we can modify the proteasome to increase its activity. There could be many other ways to do this," said the study's first author, Natura Myeku, PhD, an associate research scientist in pathology and cell biology at CUMC.
    Drugs that target proteasomes in this way should work for any disease caused by the accumulation of abnormal proteins, including Alzheimer's, Huntington's, Parkinson's and frontotemperoral dementia."
    Interesting and innovative approach to cure AD. May be in combination with TauRx Rember (now TRx0237) it can really cure AD. Simultaneous application of Rolipram and TRx0237 may have very strong synergism effect: TRx0237 will destroy/dissolve p-tau aggregates and activated proteasomes will destroy this garbage disposal.
    Tanzi should think about it: for example "PBT2 chelates Zn and other metals inside of neurons and in such way activate proteasomes" :-)

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Dec 21, 2015 12:24 PM Flag

    thanks, I'm responding to kad and other PRAN pumpers just for fun :-)
    It's fun to see how they produce stupid and ugly like that "PBT2 was the first Tau drug and we have seen clinical results" :-) We know that only Rember was claimed as tau drug.
    It will be interesting to see what kind of lie PRAN pumpers will invent when PCH will not be lifted before Feb 2016 and IND will expire (equal to rejection by FDA of Ph3 HD trial).

  • biotech_invest biotech_invest Dec 21, 2015 12:18 PM Flag

    kad, your statement "PBT2 was the first Tau drug and we have seen clinical results." is 100% ugly lie. Even if Adlard presentation was in March 08, 2013 08:30 ET we know that TauRx results about FIRST tau drug were presented in 2012 (Monte Carlo at CTAD - the 5th edition of Clinical Trials on Alzheimer’s Disease (CtaD) i.e. 1 year earlier. When Tanzi and Adlard saw these results (the first Tau Aggregation Inhibitor (TAI) in Phase 2 clinical trial involving more than 300 patients that showed a 90% reduction in the rate of disease progression over two years) they immediately added tau as a target for PBT2.
    I see that you are getting tired of producing lies about phenomenal properties of simple metal chelator and ionophore PBT2 and as..kissing of Tanzi, Adlard, Masters and other geniuses that promised to cure AD. Time will reveal them as liars that only mislead AD researchers and postponed the discovering of AD cure.
    So, keep your PRAN shares and add more at low. It will be interesting to see your comments when PRAN pps will decline to $0.50 and below. Will you bet on animal tox studies that will prove that PBT2 is safe? On bet on "new" PD project?

    Sentiment: Strong Sell

  • biotech_invest biotech_invest Dec 21, 2015 11:08 AM Flag

    kad, it's not a rubbish but a cipher :-) People with IQ below 100 can't understand it and make a conclusion that it's a "total rubbish" :-)
    "PBT2 was the first Tau drug and we have seen clinical results" is ugly lie. Everybody knows that firstly Tanzi had claimed PBT2 as anti-amyloid drug and only later he had added anti-tau function. Most likely that you are an employee of PRAN that desperately protect fraud biotech company and Tanzi. My opinion about HD project is straight and clear: it's a fake project that created to fool investors. But if FDA lift a PCH before IND expiration we will have a good possibility to make money on Ph3 start run up and later (in 2018-2019) on approaching of Ph3 results release. Everybody will decide to keep or not to keep PRAN shares through Ph3 HD (as they did at Ph2 AD recently). They will read your opinios and my and make a decision. I'm monitoring Prana during last 5 years and will be here before Prana final crash. Same about other scam biotechs.

    Sentiment: Strong Sell

SNY
38.87-0.34(-0.87%)Feb 9 4:02 PMEST